SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.
"Without new and far-reaching approaches targeting not only risk factors but also the social and logistical barriers that limit access to treatment and medical attention, diabetes will continue to exert increasingly negative effects on the quality of life of individuals, health of populations, and the strength of global economies for decades to come."
“...it is undeniable that SGLT2 inhibitors reduce the risk of cardiovascular death in patients with cardio-renal-metabolic disease. In other words, these are agents with the potential to prevent or modify the course of cardiovascular disease, including cardiovascular mortality, in multiple patient populations.”
“To treat coronary disease effectively, cardiologists must aggressively reduce inflammation and cholesterol. For appropriate patients already taking a statin, adding the anti-inflammatory drug colchicine at a dose of 0.5 mg daily has been proven to significantly lower risks of recurrent heart attack and stroke.”
“Because testosterone deficiency is not a life-threatening condition, uncertainty about cardiovascular outcomes has weighed on treatment decisions by clinicians and patients. Our findings may facilitate a more informed consideration of the potential benefits and risks of testosterone therapy among middle-aged and older men with hypogonadism.”
As the prevalence of overweight and obesity climb steadily worldwide, public health recommendations focus on lifestyle change targeting weight loss or weight maintenance in a “healthy” range. But these findings that suggest lifestyle modification to reduce CVD risk may be important even when BMI is normal. “Compared with those with the lowest level of HLI [healthy lifestyle index], even those with intermediate HLI scores, resulting from various levels of adherence to different lifestyle behaviors, have a lower CVD risk."